Search results
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Reuters via Yahoo Finance· 7 days agoGlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies ...
Supreme Court rejected military chaplains' lawsuit saying their careers were ruined after refusing...
Business Insider· 11 hours agoThe Supreme Court denied military chaplains' lawsuit claiming retaliation for refusing the COVID-19 ...
Flu vs COVID: Stark Disparity in Vaccination and Deaths
Medscape· 3 hours agoIn the first half of 2023, COVID-19 killed 42,670 people in the United States, while the flu killed...
Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline By Investing.com
Investing.com· 11 hours agoDespite a 19% decline in total company revenues to $14.9 billion, primarily due to the reduced...
Study confirms effectiveness of bivalent COVID-19 vaccine
Medical Xpress· 6 days agoThis was the first research project conducted to evaluate the immunity induced by the Pfizer...
Pfizer (PFE) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 10 hours agoWith Abrysvo, we...further expand what is currently the broadest approved range of patients for the RSV vaccine, including adults 60 years and older and...
Pfizer Stock Rises as Outlook Rises After Earnings Beat
Barrons.com· 19 hours agoPfizer bumped up its earnings guidance on Wednesday while reporting better financial results than...
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
Motley Fool via Yahoo Finance· 2 days agoThe Stock Advisor service has more than quadrupled the return...since 2002*. *Stock Advisor returns...
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
Zacks· 2 days agoBioNTech’s top line currently comprises sales of its mRNA-based COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer ...
3 Dividend Stocks to Buy and Hold for the Next Decade
Motley Fool via Yahoo Finance· 5 days agoA rebound in COVID-19 sales and counterbalancing the impending patent cliff isn't enough to make ...
